3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Hepatocellular
7
Leukemia, Myeloid, Acute
5
Recurrence
4
Hepatitis C, Chronic
4
Hepatitis C
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Respiratory Tract Infections
2
Lymphoma, Mantle-Cell
2
Infections
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Testicular Neoplasms
1
Teratoma, Testicular
1
Teratoma
1
Seminoma
1
Respiratory Syncytial Virus Infections
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Neuroblastoma
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Malignant Solid Tumor
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Cyclophosphamide
344
Cytarabine
281
fludarabine phosphate
201
Methotrexate
185
Filgrastim
159
Busulfan
147
Etoposide
135
Peripheral Blood Stem Cell Transplantation
133
fludarabine
127
Rituximab
119
Radiotherapy
111
Vincristine
102
Cyclosporine
98
Daunorubicin
96
Antilymphocyte Serum
94
Dexamethasone
91
Tacrolimus
85
Mycophenolic Acid
85
Whole-Body Irradiation
80
Melphalan
79
Idarubicin
67
Mercaptopurine
66
Imatinib Mesylate
66
Granulocyte Colony-Stimulating Factor
65
Azacitidine
65
Methylprednisolone
59
Prednisone
58
Doxorubicin
58
Clofarabine
54
sargramostim
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leukemia
×
Ribavirin
×
Clear all
NCT00559091
2022-12-22
Borden-001
Jewish General Hospital
Phase 2
Completed
18 enrolled